Det vides ikke, om forøget eksponering for metabolitten hos personer med nyresygdom i slutstadiet kan forårsage stigning af bivirkningerne, men der er ikke identificeret nogen farmakologisk aktivitet af metabolitten.
It is unknown whether the increased metabolite exposure in endstage renal disease subjects could give rise to adverse effects but no pharmacological activity of the metabolite has been identified.